Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 87
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
CRAD001C2241
NCT00419159
2.
Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
CRAD001C2454
NCT00510354
3.
Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
CRAD001C2324
NCT00510068
4.
A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Genetics, Treatment
Active
18 and over
Other
GBG 44
EudraCT No.: 2006-005834-19, NCT00567554
5.
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
Any age
Pharmaceutical / Industry
CRAD001M2301
NCT00789828
6.
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab-Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
CRAD001N2301
EUDRACT 2008-000498-40, NCT00790036
7.
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
CRAD001M2302
NCT00790400
8.
CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
2007.489/32
NCT00799188
9.
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
2004-0758
NCT00253318
10.
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
2005-0471
NCT00317720
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute